MediPharm Labs welcomes Markus Roggen to the Science Advisory Committee
MediPharm Labs (MediPharm) recently announced the establishment of our Science Advisory Committee (SAC), a group of internationally-esteemed, expert scientists, researchers and medical professionals. The SAC collaborates with MediPharm’s management team on advancements in the emerging fields of cannabinoid extraction and cannabinoid-based derivative science and serves to further enhance the company’s manufacturing platform and research practices, among other goals.
The first individual to join the SAC was Dr. Markus Roggen, supercritical CO2 extraction specialist, organic chemist, professor, and cannabis science researcher. Born in Germany, Markus pursued his chemistry doctorate by attending renowned scientific institutions across the globe. He holds a Ph. D in Chemistry from Eidgenössiche Technische Hochschule Zürich, an institution ranked among the world’s top universities and reputed for its focus on the chemistry, mathematics and physics fields. In 2018, Dr. Roggen founded Complex Biotech Discovery Ventures, a private research laboratory dedicated to cannabis science, analytics and process development.
As a member of the SAC, Markus assists MediPharm in making informed decisions about extraction processes, milling and decarboxylation techniques, post-processing methodologies, and more.
When asked why he decided to join the SAC, Markus replied “I chose to accept the advisory position as Pat and his team share my belief in what the cannabis industry will evolve into. I hope that, together, we can lead this process. MediPharm Labs feels like a pharmaceutical producer, an experience I did not have at any other cannabis production facility. As the industry is maturing, such a level of insight and precision will become the foundation of any success.”
As MediPharm delivers on its mission to become a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, alignment with industry leaders like Dr. Roggen are a natural step. “Together with our senior leadership team, the Science Advisory Committee will be instrumental as we advance the MediPharm Labs platform to drive continued and future growth, develop IP and remain on the forefront of cannabinoid-based derivative research and manufacturing globally,” says Pat McCutcheon, MediPharm CEO.
To learn more about the Science Advisory Committee, please visit medipharmlabs.com/news/press-releases.